Table 2.
Clinical and immunological characteristics at enrolment in care and ART initiation at six Ethiopian clinics (June 2012 to April 2013)
| Enrolment in care | ART initiation | |||||
|---|---|---|---|---|---|---|
| n (%) | % among men | % among women | n (%) | % among men | % among women | |
| Total | 1180 (100) | 1180 (100) | ||||
| Advanced HIV diseasea | ||||||
| Data available | 1149 (97.4) | 98.0 | 96.8 | 1180 (100) | 100 | 100 |
| Yes | 313 (27.3) | 38.3 | 20.1 | 368 (31.2) | 43.2 | 23.6 |
| No | 835 (72.7) | 61.7 | 79.9 | 812 (68.8) | 56.7 | 76.4 |
| CD4+ count, cells/µL | ||||||
| Data available | 1109 (94.0) | 6.1 | 6.0 | 1076 (91.2) | 93.9 | 89.5 |
| Median (IQR) | 263 (140 to 390) | 206 (108 to 344) | 296 (172 to 423) | 212 (119 to 288) | 178 (98 to 251) | 232 (152 to 302) |
| Clinical WHO disease stage | ||||||
| Data available | 1136 (96.3) | 96.9 | 95.7 | 1177 (99.7) | 99.8 | 99.6 |
| Stage I | 381 (33.6) | 22.5 | 40.6 | 257 (21.8) | 14.9 | 26.2 |
| Stage II | 307 (27.0) | 30.2 | 25.0 | 335 (28.5) | 28.5 | 28.5 |
| Stage III | 418 (36.8) | 43.9 | 32.2 | 540 (45.9) | 52.7 | 41.6 |
| Stage IV | 30 (2.6) | 3.4 | 2.2 | 45 (3.8) | 3.9 | 3.8 |
| ART eligibility at enrolmentb | ||||||
| Not eligible | 585 (49.6) | 40.1 | 55.5 | – | – | |
| Eligible | 564 (47.8) | 57.9 | 41.4 | – | – | |
| Unknown | 31 (2.6) | 2.0 | 3.1 | – | – | |
| History of TB treatment in HIV care | ||||||
| Yes | – | – | 150 (12.7) | 15.9 | 10.7 | |
| No | – | – | 1030 (87.3) | 84.1 | 89.3 | |
| Time between diagnosis and ART initiation | ||||||
| Median (IQR) | 8.3 months (1.1 months to 3.4 years) | |||||
| Men | 3.6 months (27 days to 2.4 years) | |||||
| Women | 1.1 years (1.2 months to 4 years) | |||||
| Time between enrolment in care and ART initiation | ||||||
| Median (IQR) | 2.9 months (15 days to 2.6 years) | |||||
| Men | 1.1 months (14 days to 1.4 months) | |||||
| Women | 5.3 months (18 days to 3.1 years) | |||||
ART, antiretroviral therapy; IQR, interquartile range; TB, tuberculosis; WHO, World Health Organization
a
advanced HIV disease at enrolment or ART initiation is defined as having a CD4+ cell count <150 cells/µL or WHO Stage IV
b
eligibility based on national Ethiopian HIV guidelines.